RU2015126651A - Способы скрининга - Google Patents

Способы скрининга Download PDF

Info

Publication number
RU2015126651A
RU2015126651A RU2015126651A RU2015126651A RU2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A RU 2015126651 A RU2015126651 A RU 2015126651A
Authority
RU
Russia
Prior art keywords
nodular
peptide
mass spectrum
peptides
light
Prior art date
Application number
RU2015126651A
Other languages
English (en)
Russian (ru)
Inventor
Джеймс ОЛСОН
Кристофер Мехлин
Марк СТРОУД
Джулиан САЙМОН
Колин КОРРЕНТИ
Патрик ПАДДИСОН
Роналд СТРОНГ
Дамон МАЙ
Original Assignee
Фред Хатчинсон Кэнсер Рисёрч Сентер
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фред Хатчинсон Кэнсер Рисёрч Сентер filed Critical Фред Хатчинсон Кэнсер Рисёрч Сентер
Publication of RU2015126651A publication Critical patent/RU2015126651A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
RU2015126651A 2012-12-10 2013-12-10 Способы скрининга RU2015126651A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261735516P 2012-12-10 2012-12-10
US61/735,516 2012-12-10
US201361794685P 2013-03-15 2013-03-15
US61/794,685 2013-03-15
PCT/US2013/074218 WO2014093406A1 (en) 2012-12-10 2013-12-10 Methods for screening

Publications (1)

Publication Number Publication Date
RU2015126651A true RU2015126651A (ru) 2017-01-16

Family

ID=49883268

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015126651A RU2015126651A (ru) 2012-12-10 2013-12-10 Способы скрининга
RU2015126650A RU2015126650A (ru) 2012-12-10 2013-12-10 Партнеры липокалина по слиянию

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015126650A RU2015126650A (ru) 2012-12-10 2013-12-10 Партнеры липокалина по слиянию

Country Status (11)

Country Link
US (4) US20140179560A1 (https=)
EP (2) EP2928914A1 (https=)
JP (2) JP2016505826A (https=)
CN (2) CN105008393A (https=)
AU (2) AU2013359426A1 (https=)
BR (2) BR112015013515A2 (https=)
CA (2) CA2913127A1 (https=)
IL (2) IL239261A0 (https=)
RU (2) RU2015126651A (https=)
SG (2) SG11201504600UA (https=)
WO (2) WO2014093403A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795983C2 (ru) * 2018-04-12 2023-05-16 Етх Цюрих Мнс-дисплей пептидов млекопитающего как инструмент для выбора антигенной детерминанты при создании вакцин

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
CN108524919A (zh) 2012-05-17 2018-09-14 延伸生物科学股份有限公司 用于改进的药物递送的载体
CN105008393A (zh) 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
KR101576904B1 (ko) * 2014-07-31 2015-12-14 (주)케어젠 파골세포 분화 및 활성 억제능을 갖는 펩타이드 및 이의 용도
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
CN107847554A (zh) * 2015-06-26 2018-03-27 弗莱德哈钦森癌症研究中心 治疗性肽及其使用方法
WO2016210376A2 (en) * 2015-06-26 2016-12-29 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
US11090358B2 (en) 2015-09-09 2021-08-17 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
CA3001833A1 (en) * 2015-10-13 2017-04-20 City Of Hope Chimeric antigen receptors containing a chlorotoxin domain
US10815290B2 (en) 2015-11-10 2020-10-27 Fred Hutchinson Cancer Research Center NKG2D decoys
CN105348392B (zh) * 2015-11-18 2019-08-02 北京华金瑞清生物医药技术有限公司 一种Nav1.7抑制剂及其改造方法
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER
US20190292243A1 (en) * 2016-08-22 2019-09-26 Fred Hutchinson Cancer Research Center Peptides and methods of use thereof
ES3015117T3 (en) 2016-08-29 2025-04-29 Fred Hutchinson Cancer Center Chelating platform for delivery of radionuclides
CN106699866A (zh) * 2016-12-13 2017-05-24 山西农业大学 一种鸡细胞外脂肪酸结合蛋白、原核表达及其纯化方法
AU2018210157B2 (en) 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) * 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
AU2018283161A1 (en) 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用
EP3727146A4 (en) 2017-12-19 2021-10-06 Blaze Bioscience, Inc. TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE
WO2019178573A1 (en) * 2018-03-16 2019-09-19 Blaze Bioscience, Inc. Truncated cartilage-homing peptides and peptide complexes and methods of use thereof
EP4076500A4 (en) * 2019-12-19 2023-12-27 Blaze Bioscience, Inc. METHOD FOR TREATING VASCULAR LESIONS AND MALFORMATIONS
CN115329965B (zh) * 2022-08-16 2025-08-01 北京有竹居网络技术有限公司 数据处理方法和电子设备
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
EP0282581A4 (en) 1986-09-19 1988-11-02 Scripps Clinic Res Monoclonal paratopic molecule directed to human ganglioside gd2.
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
EP0642353A1 (en) 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
UA29466C2 (uk) 1993-01-14 2000-11-15 Канзер Рісерч Кампейн Технолоджі, Лтд Фармацевтична композиція з антипухлинною активністю
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
WO1997043301A2 (en) * 1996-05-10 1997-11-20 Novartis Ag Identification of members of combinatorial libraries by mass spectrometry
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
AU748250B2 (en) 1997-12-05 2002-05-30 Kyogo Itoh Tumor antigen peptide derivatives
GB9809776D0 (en) * 1998-05-07 1998-07-08 Nycomed Imaging As Method
AU5197599A (en) 1998-08-12 2000-03-06 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
DE69912444T3 (de) * 1998-08-25 2010-05-06 University Of Washington, Seattle Schnelle quantitative analyse von proteinen oder proteinfunktionen in komplexen gemischen
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6629040B1 (en) * 1999-03-19 2003-09-30 University Of Washington Isotope distribution encoded tags for protein identification
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6767635B1 (en) 1999-09-14 2004-07-27 Biomedical Apherese Systeme Gmbh Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
AUPQ339899A0 (en) * 1999-10-13 1999-11-04 University Of Queensland, The Novel molecules
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
CA2427858A1 (en) 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
WO2002069896A2 (en) 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003000203A2 (en) 2001-06-26 2003-01-03 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
GB0115581D0 (en) * 2001-06-26 2001-08-15 Glaxo Group Ltd Method of mass spectometry
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
WO2003066663A2 (en) 2002-02-04 2003-08-14 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2003101474A1 (en) 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7563600B2 (en) * 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
CA2519361A1 (en) * 2003-03-21 2004-10-07 Schering Corporation Method of screening for target ligands
CN1791671A (zh) * 2003-03-21 2006-06-21 先灵公司 靶配体的筛选方法
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
WO2005053611A2 (en) 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
DE602004020570D1 (de) * 2003-12-18 2009-05-28 Biomethodes Verfahren zur ortspezifischen Massenmutagenese
DE602005019728D1 (de) 2004-04-06 2010-04-15 Transmolecular Inc Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
WO2006036928A2 (en) * 2004-09-27 2006-04-06 Wayne State University Inhibitors of matrix metalloproteinases to treat neurological disorders
GB0422901D0 (en) * 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) * 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
ATE502048T1 (de) 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
EP2147927A3 (en) 2006-03-31 2010-09-01 Transmolecular, Inc. Use of 131i-tm-601 for the diagnosis and treatment of gliomas
EP2029157A4 (en) 2006-05-19 2009-11-18 Georgia Tech Res Inst ABC TRANSPORTERLIGAND
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
CA2696303A1 (en) 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
US20110283260A1 (en) 2007-08-31 2011-11-17 Iosemantics, Llc Quality assurance tools for use with source code and a semantic model
EP2211913A4 (en) 2007-10-12 2010-12-22 Transmolecular Inc SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
CN101910845A (zh) 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
ES2658852T3 (es) 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
US9308239B2 (en) 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
US8093060B2 (en) 2008-02-28 2012-01-10 Canon Kabushiki Kaisha Multisite phosphorylated peptide (protein) recognizing compound and detection method, imaging method, alzheimer's disease diagnosing method and reagent kit using the same
CN102026671B (zh) 2008-03-14 2014-09-03 Visen医药公司 整联蛋白靶向试剂及使用其的体内和体外成像方法
CN102056617A (zh) 2008-03-20 2011-05-11 特兰斯莫莱库拉公司 血管生成的抑制
GB0807831D0 (en) 2008-04-29 2008-06-04 Cambridge Entpr Ltd Agents for imaging cell death
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
JP2009300110A (ja) 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
US20100098637A1 (en) 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
JP2010085108A (ja) 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
US20100331650A1 (en) * 2009-06-25 2010-12-30 Roche Diagnostics Operations, Inc. Episodic blood glucose monitoring system with an interactive graphical user interface and methods thereof
CN102791827B (zh) 2009-11-09 2016-11-16 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
JP5858932B2 (ja) 2010-02-04 2016-02-10 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
NZ606584A (en) * 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
EP2638173B1 (en) * 2010-11-08 2019-06-19 The Board of Trustees of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
EP3270407B1 (en) * 2010-12-28 2021-07-07 Quest Diagnostics Investments LLC Quantitation of insulin by mass spectrometry
DK2748357T3 (en) 2011-09-07 2018-07-16 X Chem Inc Methods for labeling DNA-encoded libraries
CN105008393A (zh) 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2795983C2 (ru) * 2018-04-12 2023-05-16 Етх Цюрих Мнс-дисплей пептидов млекопитающего как инструмент для выбора антигенной детерминанты при создании вакцин

Also Published As

Publication number Publication date
US20150316536A1 (en) 2015-11-05
AU2013359429A1 (en) 2015-07-09
AU2013359426A2 (en) 2015-11-05
SG11201504600UA (en) 2015-07-30
EP2928913A1 (en) 2015-10-14
IL239261A0 (en) 2015-07-30
RU2015126650A (ru) 2017-01-12
WO2014093406A1 (en) 2014-06-19
US20190101528A1 (en) 2019-04-04
AU2013359429A2 (en) 2015-11-12
AU2013359426A1 (en) 2015-07-09
CN105008393A (zh) 2015-10-28
SG11201504602VA (en) 2015-07-30
IL239262A0 (en) 2015-07-30
US20150322123A1 (en) 2015-11-12
JP2016505251A (ja) 2016-02-25
BR112015013515A2 (pt) 2017-11-14
JP2016505826A (ja) 2016-02-25
US10156559B2 (en) 2018-12-18
CA2913029A1 (en) 2014-06-19
CA2913127A1 (en) 2014-06-19
CN105189540A (zh) 2015-12-23
BR112015013525A2 (pt) 2017-11-14
WO2014093403A1 (en) 2014-06-19
EP2928914A1 (en) 2015-10-14
US20140179560A1 (en) 2014-06-26

Similar Documents

Publication Publication Date Title
RU2015126651A (ru) Способы скрининга
Jansen et al. ATP-binding cassette subfamily C member 5 (ABCC5) functions as an efflux transporter of glutamate conjugates and analogs
AU2021250887B2 (en) Immunogenic mutant peptide screening platform
Chen et al. Identification of MHC peptides using mass spectrometry for neoantigen discovery and cancer vaccine development
Lu et al. Structure-guided bifunctional molecules hit a DEUBAD-lacking hRpn13 species upregulated in multiple myeloma
US20090092553A1 (en) Monocarboxylate transporters expressed in cancer cells
Zhao et al. Fibrinogen‐derived fibrinostatin inhibits tumor growth through anti‐angiogenesis
Marucci et al. Anticancer activity study of A3 adenosine receptor agonists
Irmer et al. Syntenin Controls Extracellular Vesicle‐Induced Tumour Migration by Regulating the Expression of Adhesion Proteins on Small Extracellular Vesicles
EP3687559A2 (en) Compositions that target tumor-associated macrophages and methods of use therefor
Baumann Nonclinical development of biopharmaceuticals
Yang et al. A HSP60-targeting peptide for cell apoptosis imaging
US20220273751A1 (en) Gpcr heteromer inhibitors and uses thereof
Brunetti et al. Molecular definition of the interaction between a tumor-specific tetrabranched peptide and LRP6 receptor
Verma et al. Analysis of dynamic tyrosine phosphoproteome in LFA‐1 triggered migrating t‐cells
Foy et al. Recent advances in the characterisation of the platelet membrane system by proteomics
Rui et al. Sigma receptors as new target for multiple sclerosis
CN115298549A (zh) M蛋白测定及其用途
Sheikh et al. Lymphoma: TLR signaling dysregulation, potential proteomic techniques, therapeutic strategies, and future perspectives
WO2005119261A2 (en) Glut5 transporters expressed in cancer cells
Wilke et al. Discovery of a novel σ1 receptor antagonist by combination of unbiased cell painting and thermal proteome profiling
Zhang et al. Discovery of a Novel Dual-Targeting KRASG12D/HDAC Peptide Inhibitor for the Treatment of Pancreatic Cancer
Tuntithavornwat INTERPLAY BETWEEN EXTRINSIC MECHANICAL STIMULI AND INTRINSIC GENETIC PERTURBATION ON CYTOSKELETAL DYNAMICS
Lai et al. Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy
Pauls et al. Author contributions to Manuscript 2

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170725